Bob Linke, MBA

Bob Linke is a biopharma entrepreneur with a proven track record building and leading emerging companies through all phases of growth – from product development and clinical studies to successful commercialization, partnership and acquisitions raising over $75M in private and non-dilutive capital to fund ventures. He is formerly the Executive Chairman of IonSense, which had a successful exit to Bruker in 2022 and Embera NeuroTherapeutics. His early career was spent in big pharma at Baxter, developing and commercializing pharmaceuticals and drug delivery systems. He received his MBA from Harvard Business School.